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Abstract 
Background 
Vulva cancer is increasing in incidence and becoming more prevalent amongst younger 
women. Over 50% of patients present with advanced stage disease at Tygerberg Hospital. The 
prognosis for late stage vulvar cancer is poor and the treatment has a high morbidity. The 
reasons for delayed presentation of cancer include a lack of knowledge about the disease, 
financial constraints, psychosocial factors, transport and access to health care. 
Objective 
To determine the reasons behind the late presentation of patients with vulva cancer at 
Tygerberg Hospital and to propose strategies to reduce avoidable factors, both patient-related 
and within the health care system, leading to the delay in diagnosis. 
Methods 
This prospective cohort study included all women presenting to the Tygerberg Oncology unit 
with a new diagnosis of histologically confirmed vulvar carcinoma between November 2015 
and December 2016. An interview was conducted and a questionnaire completed. Data 
obtained included demographic, social, health seeking behavior, disease and transport related 
factors. Descriptive statistics were reported and comparisons between early and late stage 
disease were calculated using Microsoft Excel version 14 and Social Science Statistics 
Calculators. 
Results 
Fifteen of the 30 patients interviewed presented with early vulva cancer (FIGO stage 1 or 2), 
and 15 patients presented with late stage disease (FIGO stage 3 or 4). The youngest patient was 
28 years old and the oldest patient in the study was 72 years. There were no significant 
differences noted between the early and late stage disease with regards demographic, social or 
transport factors. There was no correlation between the size of the vulva lesion and delay in 
presentation. Nineteen patients (63.3%) used alternative modalities before seeking help from a 
health care worker. Although 21 (70%) women had a gynecological examination at the primary 
health facility, many were treated with antibiotics or creams before a definitive diagnosis was 
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made. Nineteen patients (63.3%) made 4 or more visits to the primary health care facility before 
being referred to Tygerberg Hospital for management. 
 
Conclusion 
A delay of diagnosis of vulva cancer can be attributed to patient delay in the lack of recognition 
and interpretation of seriousness of the symptoms of vulvar cancer.   Similar to the available 
literature, a system delay was also noted on the part of the primary health care practitioner. 
Educating women about this once rare disease and raising suspicion in health care workers 
regarding the presentation of vulva cancer might aid in earlier health seeking behavior, a 
prompter biopsy and prevent delayed diagnosis.   
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Background and Literature review 
Introduction 
Vulvar cancer in South Africa 
Vulvar cancer, once known to be a rare condition, is now increasing in incidence.  Vulvar 
cancer has been found to have an association with human papilloma virus (HPV). This 
association has shown the prevalence of vulvar cancer in younger women to be on the rise (1). 
Approximately one third of patients present with advanced disease (Figo Stage 3 and 4) (2). 
The prognosis for women with early stage vulvar cancer is good, with the overall survival rate 
at five years for Stage 1 and 2 being between 80.0% - 92.4%. The overall survival rate for 
stages 3 is between 17.4% - 64.6% and for stage 4 is 13.6% (3). At Tygerberg Hospital (TBH), 
there were 182 women diagnosed with vulvar cancer during a 14 year period (2001 - 2014).The 
mean age was 52.5years and 53.3% presented with advanced FIGO stage 3 vulvar cancer or 
higher (4). 
Treatment options for advanced stage vulvar cancer include radical tumor resection such as 
anovulvectomy, primary radiotherapy or neoadjuvant chemo-radiation followed by surgery. 
These treatment modalities are associated with increased severe morbidity and no single form 
of treatment has been noted to improve the prognosis (5). Early detection of vulvar cancer 
allows for better prognosis and treatment options with less morbidity. Identifying the reasons 
that patients present with late stage disease is an important factor in the early intervention and 
prognosis for these women. 
A delay of diagnosis of any malignancy maybe explained using the Anderson model of total 
patient delay (6). However this model focused primarily on patient delay as being most 
significant and the delay due to the health care system maybe under researched or 
underestimated. Hansen et al describes diagnostic delay using three categories, which include 
patient delay, doctor delay and system delay. Furthermore system delay includes primary and 
secondary healthcare delay as well as treatment delay. 
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Figure 1. Hansen model of delay 
A few studies have looked at the factors contributing to the late presentation and delayed 
diagnosis of vulvar cancer (2,7,8). The possible reasons may include a varied clinical 
presentation, or a lack of knowledge and awareness by the patient and the health care provider. 
Other reasons maybe transport related and access to health care, financial constraints and 
psychosocial factors.  
Clinical presentation of disease 
Symptoms of disease play a major role in health seeking behavior of an individual. Often if the 
presentation is that of a lump, swelling or bleeding it may be reported much earlier as shown 
in the study carried out by Forbes et al in 2010 (7). 
In the case of ovarian cancer, usually vague symptoms with a non visible tumour, the cancer is 
detected in the advanced stages of the disease. The anatomical location of the ovaries also plays 
a major role in the poor early detection rate. This is not the case with vulvar cancer as it usually 
presents with a visible tumor (9). The majority of women with cervical cancer on the other 
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hand present with advanced disease and this has been attributed to the lack of cervical cancer 
screening programs (10).  
Early on in vulvar cancer there are a lack of specificity of symptoms, and these may range from 
pruritis to a discharge or a burning sensation. Most women overlook these as minor ailments 
assuming that with time they will resolve.  
A cohort study done in Denmark between October 2007 and December 2007, looked at a 
sample of 161 patients diagnosed with a gynecological cancer. Nine percent of the sample 
population had vulvar cancer, and this cancer was associated with longest delay in diagnosis. 
In this study more than a third of the patients consulted the health care provider with minor 
symptoms, most often not necessitating a gynecological examination, therefore contributing to 
the delay (11). 
Patient Related factors 
Patients do not always recognize symptoms other than abnormal vaginal bleeding or an obvious 
vaginal skin lesion, as being significant enough to warrant urgent medical attention and 
therefore many patients delay visiting the doctor. Similarly a study carried out in Germany 
amongst 1010 women between 2000 and 2015, showed a delay in diagnosis between 6 to 11 
months (10). A fear of examination or the reluctance of a gynecological examination were 
possible reasons attributed to this delay.  
Other evidence that also pointed toward a time delay in health seeking behavior is the survey 
carried out in England in 2010. Those patients who did not seem to think their symptoms were 
serious delayed seeking medical attention. Other reasons noted in this study was the 
‘embarrassment’ to see the doctor or the anxiety of what the outcome might have been (7). Pati 
et al also confirmed that a lack of awareness of cancer signs and symptoms in general amongst 
patients may be partly responsible for the delay in presentation (12). 
A major challenge found in a study carried out in Ghana amongst patients with vulvar cancer 
between January 2000 and December 2014 was the high default rate in those scheduled for 
treatment. About a third of patients did not commence their planned treatment or defaulted 
radiotherapy (2).  
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Health Care worker related factors 
  
The diagnosis of the common gynecological malignancies, including cervical, endometrial and 
ovarian cancer, are more easily made compared to vulvar cancer due to its rarity. This may be 
partly due to the fact that many health care providers may not be familiar with the different 
clinical presentations of the disease itself.  Health care physicians often make an incorrect 
diagnosis like that of a Bartholin gland pathology or a simple inflammation of the vagina and 
vulva (10). A retrospective study done in Germany found a delay of 186 days when the patient 
was first diagnosed with Bartholin gland pathology and 328 days when a diagnosis of 
inflammation was made (10). 
 
Furthermore, it is important to mention that in majority of cases a gynecological examination 
is not carried out unless the patient presents with an alarming symptom such as vaginal bleeding 
(10).  This adds to the delay of diagnosing vulva cancer.  
Suspicious vulva lesions are often treated with dermatological creams and ointments for 
months prior to performing a biopsy and obtaining a histological diagnosis (6). It is crucial that 
suspicious lesions be examined and biopsied by the initial health care physician. Thirty one 
percent of women had at least 3 visits to the health care worker for vulvar symptoms before 
being diagnosed with vulvar cancer in a study carried out in New Zealand (13).    
 
A study carried out in Ghana also showed an average of 52 day delay between the date of 
histological diagnosis and reporting to the referral center for radiotherapy (2). Reasons for this 
were thought to be as a result of a complicated referral system. Health care providers need to 
be able to identify patients with a concerning diagnosis and ensure all steps are taken to speed 
up the referral from one health care facility to another in order to minimize delay. 
 
Communication between the health care physician and the patient as well as between referral 
centers play a vital role in initiating a treatment modality promptly. A survey done in England 
looking at possible reasons for delay in cancer noted that besides listening skills, many doctors 
lacked questioning skills. The ability to probe a patient further about a symptom that she may 
not recognize as alarming is key in early detection. Other shortfalls with communication were 
in the form of administration tasks e.g. Appointment miscommunication or accuracy of 
information (14). 
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Financial constraints and psychosocial factors 
Treatment costs and financial constraints play an important role in the follow up of patients 
with vulvar cancer as shown in a study carried out in Ghana, which a is low middle income 
country (2). Not all costs are covered by the medical schemes or national health plans, and 
some costs have to be covered by the patients themselves and this maybe the reason for 
defaulting follow up. This is in addition to the transport costs to and from the treatment centre. 
Forbes et al also noted in a study done in England that patients from the lowest socioeconomic 
group had the longest delay (7).  
Pati et al. in a tertiary cancer center in Odisha in India, sought after the barriers and enablers in 
cancer patients seeking treatment. Out of a total of 341 patients admitted during April and June 
2011, 68 patients were interviewed and included in the study. One of the major reasons for the 
delay in accessing medical treatment (mean 340 days) was financial constraint.  This was found 
in more than 50% of the cases (12).  
In a South African survey carried out in 2009, it was noted that 80% of ill patients seek medical 
attention from traditional healers and this may be a contributing factor to a delay in detection 
of cancer in this country (15). A similar finding in a study done in Ghana also confirmed that 
many patients sought alternative treatment and only presented to a health care facility upon 
progression of disease and lack of symptom relief. Therefore alternative medicine may also 
contribute to a delayed diagnosis. 
The aim of this study was to look into avoidable factors, patient as well as the health care 
system related, that led to a delay in the diagnosis of vulvar cancer. 
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Methods 
Aims and Objectives 
Primary : 
To establish the factors that contribute to the late stage presentation of patients with 
vulvar cancer, at TBH gynaecological oncology unit. 
Secondary : 
To assess the contributing factors and propose strategies to reduce this delay. 
Methods and materials 
Ethics approval was obtained prior to the start of the study. All female patients who presented 
to Tygerberg Hospital oncology unit with a histologically confirmed vulvar carcinoma were 
invited to participate in the study. A semi structured interview was conducted in the preferred 
language or with an aid of interpreter with each patient by the primary investigator.  
Inclusion criteria 
1. Patients diagnosed at TBH or referred with a confirmed diagnosis
2. English, afrikaans or xhosa speaking patients
3. Histological confirmation of vulvar cancer
4. Ability to give informed consent
Exclusion criteria 
1. Patients with recurrent disease
2. Patients with vulvar intraepithelial lesions
3. Previous surgical or radiotherapy treatment for vulvar cancer
4. Severe physical or mental disability
5. Acutely ill patient
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Study design 
This was a prospective cohort study that was conducted between November 2015 and 
December 2016 at the TBH  oncology unit. Women who presented to the oncology unit and 
met the inclusion criteria were invited to participate in the study. Informed consent was 
obtained (Appendix A) and verbal explanation was given regarding the study. The interview 
was carried out either at the first visit to TBH oncology unit or during the preoperative stay. 
A questionnaire (Appendix B) was completed  by each women which included demographic 
information such as age, marital status, residential address, occupation and education. Data 
was also obtained during the interview on health seeking behaviour, symptoms, reasons for 
seeking medical attention, enablers and barriers involved in accessing health care, as well as 
the time lapse at each point in medical care. An additional open ended question was also 
included regarding the patient’s initial thoughts and concerns about the symptoms and 
diagnosis. Each patient was given a study number and the patients name or hospital number 
did not appear on the questionnaire in order to maintain confidentiality. 
Statistical analysis 
Data was extracted from each questionnaire and transcribed onto a MS Excel spread sheet by 
the principal investigator. Random checks were performed by the supervisor to protect against 
transcription errors. Descriptive statistics were presented as means with ranges and total 
numbers with percentages. Statistical analysis was carried out using the Chi square test and 
the Fisher exact test with significance set at p<0.05. Means were compared using the Student 
T test. Statistics were calculated using Microsoft Excel version 14 and Social Science Statistics 
Calculators (http://www.socscistatistics.com). 
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Results 
A total of 32 patients were identified to participate in the study. Two patients were excluded 
due to death and severe illness. Consent was obtained and the questionnaire was completed by 
30 patients. Fifteen patients presented with early stage vulvar cancer (FIGO stage 1 or 2), and 
15 presented with advanced stage vulvar cancer (FIGO stage 3 or 4) (Figure 1). 
Figure 2. Patients with vulvar cancer according to FIGO stage 
Socio-demographic data : 
The mean age of woman included in our study was 44.63 yrs (SD 11.3) with the youngest being 
28 years old and the oldest was 72 years of age, both presenting with stage 1 disease. There 
were no significant differences noted in those with early or late disease with regards to age, 
education, employment or marital status as shown in Table 1. Eighteen women (60 %) gave no 
family history of cancer. Seventeen women (57%) were HIV positive. Nine of these women 
presented with early stage disease and eight with late stage disease. 
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Table 1. Socio-demographic variables 
Disease: 
The average size of the lesion in the early stage of vulvar cancer was 40.8 mm  (10 - 80mm), 
and in the late stage 58.3mm (25 – 120mm), which was statistically significant as expected 
(p=0.002).  There was no correlation with a larger lesion and duration of symptoms (p=0.510). 
No correlation between size of lesion and number of visits before referral (p=0.464) was noted. 
There was no association between the size of the lesion and time to first health care encounter 
(p=0795) or time to first visit at Tygerberg (p=1). 
Transport and access to healthcare: 
Transport concerns were evaluated and it was noted that most women lived within a 10km 
radius of a health care facility, with the closest hospital less than 60 min away for majority of 
women. Ten women (66.6%) with early stage disease lived within 30 minutes from the nearest 
clinic and eight (53%) of them walked to their nearest clinic. Fourteen women (93%) that had 
late stage disease lived within 30 minutes from the nearest clinic and 11 (73.3%) of them 
walked to their nearest clinic (see Table 2). The majority of women with late stage disease 
lived within 60 minutes to the nearest hospital. 
Early Stage Late Stage p Value 
Age (SD) 44.86 yr (12.9) 44.46 yr (9.7) p = 0.912 
Single 7 5 p = 0.456 
No higher education 6 7 p = 0.712 
Unemployed 11 12 Fisher exact = 1 
Family history of cancer 6 6 p = 0 
HIV 9 8 p = 0.712 
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Table 2. Access to health facility 
Number of patients 
Early Stage Late Stage p value 
Walk to nearest clinic 8 11 p = 0.289 
Public transport to hospital 10 11 p = 0.713 
Less than 30min to clinic 10 14 p = 0.092 
Less than 60min to hospital 10 14 p = 0.092 
Less than 5km 8 9 p = 0.712 
Health worker and patient delay: 
Symptoms and health seeking behavior were assessed during the interview and are shown in 
Figure 3. 
Figure 3 Patient and Health care worker related factors 
Fourteen women (93%) with early stage disease waited for longer than 6 months before seeking 
medical attention with early stage disease. Eleven women (73%) with late stage disease waited 
longer than 6 months before seeking medical attention. Only two women (6%) were seen at 
Tygerberg hospital Oncology unit within 3 months of presenting symptoms. One was 
diagnosed with late stage and one with early stage disease. 
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Nineteen women (63%) used alternative treatment modalities such as over the counter 
ointments and salt water sitz baths, prior to their first consultation.  Nine women (30%) did not 
have a gynecological examination during their first consultation for the symptoms. Four of 
these women were diagnosed with early stage disease and 5 with late stage. No significant 
difference was noted in the size of the vulvar lesion in patients who had undergone an 
examination. 
 
Fifteen women made more than four visits to a healthcare facility for their initial presentation 
before being referred. Eight of these women had early stage and seven had late stage disease. 
When comparing early and late stage disease, there was no statistically significant difference 
between the numbers of visits prior to referral to Tygerberg oncology unit (p = 0.92). Three 
women (10%) missed scheduled follow up appointments at their health center. Of the three 
women, one had stage 4 disease and presented five months after initially seen at the primary 
health care facility, to Tygerberg hospital. Two women had stage 1 disease and presented more 
than a year later. All 30 women were followed up within three months for the results of the 
biopsies. 
 
Social factors: 
 
Of the total of 30 women that were interviewed, 23 women had a support system at home. 
Twelve of these women, as noted in figure 3 below, presented with early stage disease and 11 
with late stage disease. Fifteen of the nineteen women had shared their concerns with a partner. 
Eleven women had no partner at the time. 
 
 
Figure 4 Social factors in early and late stage 
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During the interview an open ended question regarding thoughts and concerns of each patient 
highlighted common themes of fear and a sense of embarrassment. Thirteen women thought 
the initial lesion was a “pimple” or an “abscess” and thought “it would go away”. Seven women 
suspected the lesion as part of a “sexual infection”, and three women thought the lesion to be 
a “wart”. It is interesting to note that one patient assumed that her symptoms were not due to a 
medical condition, but rather “caused by her ancestors punishing her because her brother did 
not undergo the proper traditional way of initiation”. 
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Discussion 
 
Socio demographic 
 
An equal number of women presented with early and late stage disease in our study. A survey 
conducted in England assessing the risk factors for the delay in symptomatic presentation 
amongst 1999 cancer patients concluded that 21% of patients delayed presentation for more 
than three months, and this was associated with socioeconomic deprivation (7).We did not 
corroborate these findings and found no difference when comparing socioeconomic variables 
between late and early stage cancer. 
 
Recent data on advanced vulvar cancer and age suggests that older women have higher 
proportions of advanced stage disease, but this was not found in our study (8). Women in our 
study had a mean age of 44.63 years with no difference in the mean age between early and late 
stage disease. The young age of patients with vulvar cancer in this study is attributed to the 
high rate of HPV infection in our population (4). 
 
HIV infection is a risk factor for persistent HPV disease and vulvar cancer. Our findings 
concurred with the literature, as 57 % of the study population was HIV positive. The prevalence 
of HIV amongst those patients with early and late disease was similar. Out of the total 30 
women, 17 were HIV positive with an average age of 39.7 years (SD 9.4; range 28-63 years) 
confirming that HIV is a major risk factor for vulvar cancer in younger women. 
 
Transport and access to health care 
 
Most women had relatively easy access to a health care facility, and transport to the closest 
clinic or hospital proved to be of no significant relevance with regards to delay of presentation. 
This is in contrast to a study done in Ghana where transport and transport costs played a role 
in delay of presentation (2). 
 
  
Stellenbosch University  https://scholar.sun.ac.za
 21 
Patient delay factors 
 
Patient delay was a key factor as noted by several other studies. Most patients did not recognize 
early symptoms as being serious in nature and delayed visiting the local clinic or hospital due 
to a lack of information or ignorance regarding vulvar cancer. Approximately 20 patients 
thought, “it was a pimple or an abscess and it will go away.” One patient shared her concerns 
that it was the result of a “poorly healed episiotomy” that she sustained during childbirth. Only 
when symptoms of pruritus and a progressively enlarging skin lesion became unbearable did 
most patients seek medical attention. The majority of patients attempted other forms of 
treatment e.g.  “over the counter” ointments, and salt water sitz baths before going to the clinic. 
Perhaps a lack of alarming symptoms as noted in many other studies (16), adds to the absence 
of suspicion of the cancer diagnosis and hence the prolonged delay. There was no admission 
to the use of traditional medicine in our study population, as documented in previous studies 
(15). Even though one patient had assumed her symptoms were “caused by the ancestors 
because her brother did not complete his initiation as part of tradition”, she did not admit to the 
use of traditional medicine.  There was a lack of awareness of this challenging disease. 
Embarrassment, shyness and fear were key elements that were found to be contributing to the 
delay of presentation. When asked about their initial thoughts during the interviews, many 
patients assumed their symptoms were due to a sexually transmitted infections and some 
thought it was as a result of HIV. 
 
Health care delay 
 
In our study, a median of four visits (range 0-18) was made before any women with early or 
late vulvar cancer was referred to Tygerberg Hospital. Misdiagnosis contributed to the delay 
in the diagnostic process, as patients had to follow up repeatedly before a biopsy was 
considered. Perhaps as a result of the rarity of vulvar cancer in previous years, many health 
care providers fail to recognize the symptoms and therefore are not prompted to consider it as 
a differential diagnosis. The lack of performance of a gynecological examination after the 
initial complaint was not found to be statistically significant in the delaying of the diagnosis.  
Twenty-one women (70%) had a gynecological examination performed by either the treating 
sister or the doctor at the clinic, however most of the women were still treated for a sexually 
transmitted infection with an antibiotic or ointment after the initial consult. 
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We aimed at assessing the possibility of delay between referral and diagnosis during our 
interviews, however as noted above, there was no delay after the suspicious lesions were 
biopsied and a histological diagnosis was confirmed. All patients followed up within three 
months (or earlier) of diagnosis at our oncology unit, confirming that the referral process 
between the surrounding primary health care facilities and the Tygerberg Hospital Oncology 
unit is a relatively smooth one. 
 
Social 
 
The initial thoughts and concerning factors were shared by all the women during the interviews, 
and words like “embarrassed”, “scared”, “worried” and “shy” were among those most 
frequently used. There was a heightened sense of embarrassment amongst the women we 
interviewed. Most women had a support system at home. Fifteen of the nineteen (78.9%) 
women in a relationship did share concerns of their diagnosis with their partners. Since many 
assumed their diagnosis was linked somehow to that of an STI, the stigma attached to the 
symptoms and the link to promiscuity may play a substantial role in keeping patients from 
seeking health care. Many studies have mentioned patients reporting a worry about wasting the 
doctor’s time with trivial complaints; this was however not mentioned during any of our 
interviews (7). 
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Conclusion 
 
In contrast to other studies socioeconomic factors, transport issues and seeking help from 
traditional healers played no significant role in the delayed presentation of vulvar cancer in our 
study. Our study supports other studies in that the patient delay factor plays a big role. 
Recognition and interpretation of symptoms, as well as health seeking behaviour did seem to 
be a common factor amongst those patients who did present late. 
 
Overall in our study, patients that presented with early and advanced disease had to make 
repeated visits before a diagnosis was made and the correct chanels followed. This is in keeping 
with many other studies that have shown a system delay on the part of the primary health care 
practitioner. Nineteen patients had four or more visits to the primary health care facility before 
referral to Tygerberg. Although 70% had a gynaecological examination at the primary health 
facility, many of these patients were treated with antibiotics or creams before a definitive 
diagnosis was made, suggesting that Health care workers do not recognise the vulvar pathology 
as cancer. 
 
The only recommendations we can infer from our study is to create an awareness of the disease 
amongst the female population. Perhaps enlightening women about symptomology might alert 
them to seek health care ealier.. An increase of vulvar cancer among younger age women in 
the South African population is related to the high prevalence of HPV. HPV vaccinations to 
young women might see a decrease in vulva cancer in the future. Educating the younger women 
on sexual behaviour and the importance of barrier methods of contraception might also prove 
beneficial. 
 
In order to reduce a delay on the part of the health care practitioner, a reminder of this once 
rare disease and its often vague presentation might increase suspicion. An increased suspicion 
will provoke an increase in action in excluding vulva cancer at a much earlier stage. The 
importance of  a gynaecological examination and biopsy if needed cannot be overemphasized 
in detecting vulva cancer. Doctors and nurses who are faced with the patient at first contact 
should be encouraged to have a low threshold for biopsy to rule out any malignancy on 
suspicious vulva lesions.  Health care providers who work at HIV clinics and colposcopy 
cinics, where women at high risk of HPV infection are encountered, should be especially 
vigilant. 
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Creating a public awareness of this disease, as has been done with other forms of cancer, will 
aid in removing the stigma attached to vulvar cancer and this may assist patients in overcoming 
the overwhelming emotions of fear and embarassment and in turn present with earlier stage 
disease. 
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Appendix A 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: 
 
 
 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATOR: 
 
ADDRESS: 
 
 
 
CONTACT NUMBER: 
 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand.  It 
is very important that you are fully satisfied that you clearly understand what this research 
entails and how you could be involved.  Also, your participation is entirely voluntary and you 
are free to decline to participate.  If you say no, this will not affect you negatively in any way 
whatsoever.  You are also free to withdraw from the study at any point, even if you do agree 
to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
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international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
 
What is this research study all about? 
The study will be conducted at Tygerberg Hospital where approximately 20-30 patients 
presenting to the Gynecology oncology unit will be recruited. Vulva cancer is a rare 
condition and most patients who present with this diagnosis are in the advanced stages 
already.  Therefore the aim of this study will be to try and understand the reasoning behind 
the late clinical presentation, in an attempt to encourage earlier diagnosis and treatment.  
 
 
Why have you been invited to participate? 
To assist us in finding out more regarding events surrounding the diagnosis of vulva cancer 
and how we can improve referral of patients with this disease to an oncology unit. 
 
 
What will your responsibilities be? 
To simply complete the questionnaire to the best of your capacity.  
 
 
Will you benefit from taking part in this research? 
You will not benefit from this research project however it is for the benefit of future patients 
with the same diagnosis. 
 
 
 
Are there in risks involved in your taking part in this research? 
There are no risks whatsoever for you taking part in this research. 
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If you do not agree to take part, what alternatives do you have? 
It is entirely your wish if you would not like to take part in this research study, and we would 
respect that fully. 
 
 
Who will have access to your medical records? 
 The information collected will be treated as confidential and protected.  If it is used in a 
publication or thesis, the identity of the participant will remain anonymous.  Only the 
investigators and supervisors of this research study will have access to this information. 
 
 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
There is no risk of injury should you participate in this study. 
 
 
Will you be paid to take part in this study and are there any costs involved? 
 
No you will not be paid to take part in the study, and there will be no costs involved for you, if 
you do take part. 
 
 
Is there any thing else that you should know or do? 
 
 You can contact Dr S Shah at tel 0219384424 if you have any further queries or encounter 
any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. Agree to take part in a 
research study entitled (insert title of study). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in 
a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurized to take part. 
 I may choose to leave the study at any time and will not be penalized or prejudiced 
in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2005. 
 
 
 
......................................................................   .............................................................. 
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… Declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2005. 
 
 
 
......................................................................   .............................................................. 
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… Declare that: 
 
 I assisted the investigator (name) ………………………………………. To explain 
the information in this document to (name of participant) 
……………..…………………………….. Using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……………….. 
 
 
 
......................................................................   .............................................................. 
Signature of interpreter Signature of witness 
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Appendix B 
No……….. 
Questionnaire     
Personal info: 
 
1. Age: 
 
2.  Relationship status:    Single 
       Married 
       Divorced 
       Separated 
       Other……….. 
 
3.  Level of education:   Less than High School 
      High School 
      College/ University 
      Postgraduate 
 
4.  Employment Status: Employed Unemployed 
 
5.  Where do you live? 
 
6.  Do you live alone? Yes No 
     Is there a support system at home? Yes No 
 
Travel info: 
 
7.  How do you travel to your nearest clinic?  
     How do you travel to hospital? 
 
8.  How long does it take you to get from your home to the nearest clinic? 
     How long does it take you to get from your home to hospital? 
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9.  What is your travelling distance to the nearest available clinic?  
      Less than 5Km 5-10Km More than 10 
 
 
Symptoms: 
 
10.  Is there a history of cancer in the family? Yes No 
 If yes, what:  ……………………………………………………………..................... 
 
11.  When did you first notice the lesion/symptom?  .……………………………………….. 
 
12.  How long after noticing the lesion for the first time did you go to the local clinic/ GP/ day 
hospital? 
0-3 Months 
3-6 Months 
6-12 Months 
More than 1 Year 
 
13.  How long after did you visit TBH for the first time? 
0-3 Months 
3-6 Months 
6-12 Months 
More than 1 Year 
 
14. Did you miss any appointments following your first visit to the clinic regarding this 
condition? 
Yes 
No 
 
 
15. How many visits did you make to the clinic for the same symptom before you got a referral 
date for TBH?  …………..……………………………………………………….. 
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16.  Did the doctor examine the genital area / private parts after your first complaint?  
Yes 
No 
 
17.  When was the first biopsy taken?  ……………………………………………………….. 
 
18.  How long after the biopsy was done did you follow up for the result? 
0-3 Months 
3-6 Months 
6-12 Months 
 
19.  Did you try any other treatment before coming to hospital?  Yes No 
 
20.  HIV status: 
 
 
Social: 
 
21.  What were your initial thoughts when you first noticed the lesion / symptom? 
………………………………………………………………………………………………….. 
 
22.  Did you share your concerns with your partner/husband prior to first consultation? 
Yes 
No 
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